Novartis (Canada)

Recent papers from Novartis (Canada)

1. Cost-Effectiveness Analysis of Ribociclib plus an Aromatase Inhibitor (AI) Versus AI Alone in the Adjuvant Treatment of Stage II and III Pre- and Postmenopausal Women with HR+/HER2− Early Breast Cancer (EBC): A Canadian Payer PerspectivePharmacoEconomics - Open · 2026
2. Societal and Healthcare Costs of Post-IDFS Events Following Adjuvant Ribociclib Plus an Aromatase Inhibitor (AI) Versus AI Alone in Pre- and Postmenopausal Women with Early HR+/HER2- Breast Cancer in CanadaCurrent Oncology · 2026
3. Validation of Handheld Ultrasound Devices for Point of Care Use in Rheumatology Study- Focus on Synovitis, Doppler Activity, Erosions, and Tendon LesionsThe Journal of Rheumatology · 2026
4. Longitudinal Performance of the Psoriasis Epidemiology Screening Tool (PEST) in Canada and Latin America: Results from the Prospective, Observational, 5-Year PURE RegistryDermatology and Therapy · 2026
5. The prevalence, health care resource utilization, and clinical characteristics of individuals with atherosclerotic cardiovascular disease in ManitobaCJC Open · 2026
6. Lipoprotein(a) Levels and Major Adverse Cardiovascular Events in Alberta, Canada: A Retrospective Cohort StudyCJC Open · 2026
7. Psilocybin improves novel object recognition in a rat model of Fragile X Syndrome through the modulation of the BDNF/TrkB signaling pathwayNeuropsychopharmacology · 2026
8. Eye tracking as a digital biomarker in neurodegenerative diseasesJournal of Neurology · 2026
9. Effects of Atrasentan on Kidney Gene Transcription, Mesangial Cell Proliferation, and Proteinuria in IgA NephropathyKidney360 · 2025
10. Evaluation of Recurrence Rate in Canadian Patients With Stage II/III HR+/HER2− Early Breast Cancer in the Real-World SettingBreast Cancer Basic and Clinical Research · 2025
11. Outcomes, Safety and Tolerability of Sacubitril-Valsartan over 3 years of Follow-up in Canadian Practice: Insights from the PARTHENON RegistryCJC Open · 2025
12. Characterization of lipoprotein (a) testing in Alberta, Canada: a retrospective cohort studyAtherosclerosis · 2025
13. Optimizing the commercial manufacturing of tisagenlecleucel for patients in Japan: A 4-year experiential journeyRegenerative Therapy · 2025
14. A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancerBreast Cancer Research and Treatment · 2025
15. Natural Language Processing to Assess Atherosclerotic Cardiovascular Disease, Diabetes, and Familial Hypercholesterolemia Lipid Management in CanadaJournal of Population Therapeutics and Clinical Pharmacology · 2025
16. Engaging children and adolescents in the design and conduct of paediatric researchFrontiers in Pediatrics · 2024
17. The Canadian Heart Failure (CAN-HF) Registry: A Canadian Multicentre, Retrospective Study of Outpatients with Heart FailureCJC Open · 2024
18. A Canadian real world prospective observational study assessing the impact of hormone therapy ± targeted therapy in the treatment of HR+ HER2- advanced breast cancer2024
19. Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Living Treatment Recommendations for the Management of Axial SpondyloarthritisThe Journal of Rheumatology · 2024
20. Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registryArchives of Dermatological Research · 2024